{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:21:59Z","timestamp":1787062919852,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00210-026-05366-x","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:02:14Z","timestamp":1778122934000},"page":"16139-16152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Divergent neuropsychiatric and systemic toxicity profiles of abemaciclib and palbociclib: a triangulation study integrating pharmacovigilance, genetic epidemiology, and multi-omics profiling"],"prefix":"10.1007","volume":"399","author":[{"given":"Zijian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaochun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fucheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"3","key":"5366_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies [J]. Multivariate Behav Res 46(3):399\u2013424","journal-title":"Multivariate Behav Res"},{"issue":"4","key":"5366_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/stem.616","volume":"29","author":"P Beukelaers","year":"2011","unstructured":"Beukelaers P, Vandenbosch R, Caron N et al (2011) Cdk6-dependent regulation of G(1) length controls adult neurogenesis [J]. Stem Cells 29(4):713\u2013724","journal-title":"Stem Cells"},{"issue":"10","key":"5366_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","volume":"11","author":"JE Bower","year":"2014","unstructured":"Bower JE (2014) Cancer-related fatigue\u2013mechanisms, risk factors, and treatments [J]. Nat Rev Clin Oncol 11(10):597\u2013609","journal-title":"Nat Rev Clin Oncol"},{"key":"5366_CR4","doi-asserted-by":"crossref","unstructured":"Bower JE, Lamkin DM (2013) Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications [J]. Brain Behav Immun, 30 Suppl(0) : S48\u201357.","DOI":"10.1016\/j.bbi.2012.06.011"},{"issue":"5","key":"5366_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"32","author":"S Burgess","year":"2017","unstructured":"Burgess S, Thompson SG (2017) Interpreting findings from Mendelian randomization using the MR-Egger method [J]. Eur J Epidemiol 32(5):377\u2013389","journal-title":"Eur J Epidemiol"},{"key":"5366_CR6","doi-asserted-by":"publisher","first-page":"175883592413020","DOI":"10.1177\/17588359241302018","volume":"16","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xie Y, Sang D et al (2024) Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+\/HER2-metastatic breast cancer patients: a multicenter study (YOUNGBC-28) [J]. Ther Adv Med Oncol 16:17588359241302018","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"5366_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1158\/1541-7786.MCR-17-0468","volume":"16","author":"EM Cousins","year":"2018","unstructured":"Cousins EM, Goldfarb D, Yan F et al (2018) Competitive kinase enrichment proteomics reveals that abemaciclib inhibits GSK3\u03b2 and activates WNT signaling [J]. Mol Cancer Res 16(2):333\u2013344","journal-title":"Mol Cancer Res"},{"issue":"5","key":"5366_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100231","volume":"6","author":"M Del Re","year":"2021","unstructured":"Del Re M, Omarini C, Diodati L et al (2021) Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. ESMO Open 6(5)","journal-title":"ESMO Open"},{"issue":"2","key":"5366_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000499534","volume":"14","author":"J Ettl","year":"2019","unstructured":"Ettl J (2019) Management of adverse events due to cyclin-dependent kinase 4\/6 inhibitors [J]. Breast Care (Basel) 14(2):86\u201392","journal-title":"Breast Care (Basel)"},{"issue":"20","key":"5366_CR10","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer [J]. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"32","key":"5366_CR11","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer [J]. J Clin Oncol 35(32):3638\u20133646","journal-title":"J Clin Oncol"},{"issue":"12","key":"5366_CR12","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","volume":"59","author":"SL Groenland","year":"2020","unstructured":"Groenland SL, Mart\u00ednez-Ch\u00e1vez A, Van Dongen MGJ et al (2020) Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib [J]. Clin Pharmacokinet 59(12):1501\u20131520","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"5366_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1017\/S0033291720005127","volume":"51","author":"G Hammerton","year":"2021","unstructured":"Hammerton G, Munaf\u00f2 MR (2021) Causal inference with observational data: the need for triangulation of evidence [J]. Psychol Med 51(4):563\u2013578","journal-title":"Psychol Med"},{"issue":"5","key":"5366_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106714","volume":"26","author":"W He","year":"2023","unstructured":"He W, Demas DM, Shajahan-Haq AN et al (2023) Modeling breast cancer proliferation, drug synergies, and alternating therapies. iScience 26(5)","journal-title":"iScience"},{"issue":"1","key":"5366_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-0958-2","volume":"20","author":"JK Kish","year":"2018","unstructured":"Kish JK, Ward MA, Garofalo D et al (2018) Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced\/metastatic breast cancer treated in community oncology practice in the USA one year post approval [J]. Breast Cancer Res 20(1)","journal-title":"Breast Cancer Res"},{"issue":"11","key":"5366_CR16","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.ccell.2024.09.009","volume":"42","author":"R Kudo","year":"2024","unstructured":"Kudo R, Safonov A, Jones C et al (2024) Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion [J]. Cancer Cell 42(11):1919\u201335.e9","journal-title":"Cancer Cell"},{"issue":"6","key":"5366_CR17","first-page":"1866","volume":"45","author":"DA Lawlor","year":"2016","unstructured":"Lawlor DA, Tilling K, Davey SG (2016) Triangulation in aetiological epidemiology [J]. Int J Epidemiol 45(6):1866\u20131886","journal-title":"Int J Epidemiol"},{"key":"5366_CR18","unstructured":"Lee JJ, Wedow R, Okbay A, et al (2018) Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals [J]. Nat Genet, 50(8) : 1112\u201321."},{"issue":"2","key":"5366_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/cpt.2021","volume":"109","author":"J Li","year":"2021","unstructured":"Li J, Jiang J, Wu J et al (2021) Physiologically based pharmacokinetic modeling of central nervous system pharmacokinetics of CDK4\/6 inhibitors to guide selection of drug and dosing regimen for brain cancer treatment [J]. Clin Pharmacol Ther 109(2):494\u2013506","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"5366_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ajhg.2018.09.009","volume":"103","author":"S Ligthart","year":"2018","unstructured":"Ligthart S, Vaez A, V\u00f5sa U et al (2018) Genome analyses of >200,000 individuals identify 58 loci for chronic inflammation and highlight pathways that link inflammation and complex disorders [J]. Am J Hum Genet 103(5):691\u2013706","journal-title":"Am J Hum Genet"},{"issue":"1","key":"5366_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-024-00770-6","volume":"25","author":"W Lin","year":"2024","unstructured":"Lin W, Zeng Y, Weng L et al (2024) Comparative analysis of adverse events associated with CDK4\/6 inhibitors based on FDA\u2019s adverse event reporting system: a case control pharmacovigilance study. BMC Pharmacol Toxicol 25(1)","journal-title":"BMC Pharmacol Toxicol"},{"issue":"20","key":"5366_CR22","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1038\/s41388-019-0695-8","volume":"38","author":"S Llanos","year":"2019","unstructured":"Llanos S, Megias D, Blanco-Aparicio C et al (2019) Lysosomal trapping of palbociclib and its functional implications. Oncogene 38(20):3886\u2013902","journal-title":"Oncogene"},{"key":"5366_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105954","volume":"178","author":"A Mart\u00ednez-Ch\u00e1vez","year":"2022","unstructured":"Mart\u00ednez-Ch\u00e1vez A, Loos NHC, Lebre MC et al (2022) ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. Pharmacol Res 178","journal-title":"Pharmacol Res"},{"issue":"2","key":"5366_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40264-012-0014-6","volume":"36","author":"SN Pal","year":"2013","unstructured":"Pal SN, Duncombe C, Falzon D et al (2013) WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems [J]. Drug Saf 36(2):75\u201381","journal-title":"Drug Saf"},{"issue":"10","key":"5366_CR25","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, Gregoire F, Fourrier-Reglat A et al (2007) Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias [J]. Drug Saf 30(10):891\u2013898","journal-title":"Drug Saf"},{"issue":"2","key":"5366_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/jpet.115.228213","volume":"355","author":"KE Parrish","year":"2015","unstructured":"Parrish KE, Pokorny J, Mittapalli RK et al (2015) Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4\/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther 355(2):264\u201371","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"5366_CR27","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","volume":"6","author":"A Patnaik","year":"2016","unstructured":"Patnaik A, Rosen LS, Tolaney SM et al (2016) Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov 6(7):740\u201353","journal-title":"Cancer Discov"},{"issue":"1","key":"5366_CR28","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2024.2387323","volume":"24","author":"Y Peng","year":"2025","unstructured":"Peng Y, Zhou Y, Zhou X et al (2025) A disproportionality analysis of CDK4\/6 inhibitors in the FDA Adverse Event Reporting System (FAERS) [J]. Expert Opin Drug Saf 24(1):25\u201333","journal-title":"Expert Opin Drug Saf"},{"key":"5366_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1278682","volume":"14","author":"R Prevost","year":"2023","unstructured":"Prevost R, Chretien B, Minoc EM et al (2023) Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4\/6 inhibitors: a pharmacovigilance study using the World Health Organization\u2019s database [J]. Front Pharmacol 14","journal-title":"Front Pharmacol"},{"issue":"9","key":"5366_CR30","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1124\/dmd.114.062745","volume":"43","author":"TJ Raub","year":"2015","unstructured":"Raub TJ, Wishart GN, Kulanthaivel P et al (2015) Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos 43(9):1360\u201371","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"5366_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies [J]. Nucleic Acids Res 43(7)","journal-title":"Nucleic Acids Res"},{"issue":"16","key":"5366_CR32","doi-asserted-by":"publisher","first-page":"8761","DOI":"10.1021\/acs.jmedchem.9b01101","volume":"63","author":"R Rodr\u00edguez-P\u00e9rez","year":"2020","unstructured":"Rodr\u00edguez-P\u00e9rez R, Bajorath J (2020) Interpretation of compound activity predictions from complex machine learning models using local approximations and Shapley values. J Med Chem 63(16):8761\u201377","journal-title":"J Med Chem"},{"issue":"3","key":"5366_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s10549-018-05125-4","volume":"174","author":"HS Rugo","year":"2019","unstructured":"Rugo HS, Finn RS, Di\u00e9ras V et al (2019) Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 174(3):719\u201329","journal-title":"Breast Cancer Res Treat"},{"issue":"6421","key":"5366_CR34","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1126\/science.aas9090","volume":"362","author":"M Ruscetti","year":"2018","unstructured":"Ruscetti M, Leibold J, Bott MJ et al (2018) NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362(6421):1416\u20131422","journal-title":"Science"},{"issue":"7","key":"5366_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K et al (2013) Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci 10(7):796\u2013803","journal-title":"Int J Med Sci"},{"issue":"9","key":"5366_CR36","doi-asserted-by":"publisher","first-page":"873","DOI":"10.18632\/oncotarget.27904","volume":"12","author":"I Schlam","year":"2021","unstructured":"Schlam I, Tolaney SM (2021) Is there a role for CDK 4\/6 inhibitors in breast cancer brain metastases? Oncotarget 12(9):873\u2013875","journal-title":"Oncotarget"},{"issue":"25","key":"5366_CR37","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P et al (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy [J]. J Clin Oncol 35(25):2875\u20132884","journal-title":"J Clin Oncol"},{"issue":"7708","key":"5366_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41586-018-0175-2","volume":"558","author":"BB Sun","year":"2018","unstructured":"Sun BB, Maranville JC, Peters JE et al (2018) Genomic atlas of the human plasma proteome. Nature 558(7708):73\u20139","journal-title":"Nature"},{"issue":"2","key":"5366_CR39","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s11096-023-01687-6","volume":"46","author":"T Takeda","year":"2024","unstructured":"Takeda T, Sugimoto S, Matsumoto J et al (2024) A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases. Int J Clin Pharm 46(2):536\u201341","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"5366_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455\u201361","journal-title":"J Comput Chem"},{"issue":"20","key":"5366_CR41","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J et al (2018) Overall Survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926\u201336","journal-title":"N Engl J Med"},{"issue":"29","key":"5366_CR42","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1038\/s41388-020-1354-9","volume":"39","author":"V Wagner","year":"2020","unstructured":"Wagner V, Gil J (2020) Senescence as a therapeutically relevant response to CDK4\/6 inhibitors. Oncogene 39(29):5165\u201376","journal-title":"Oncogene"},{"issue":"10","key":"5366_CR43","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40261-024-01396-6","volume":"44","author":"Z Yu","year":"2024","unstructured":"Yu Z, Guan M, Liao X (2024) Neurological and psychiatric adverse events associated with cyclin-dependent kinase 4\/6 inhibitors in breast cancer patients: insights from a pharmacovigilance study via the FDA adverse event reporting system. Clin Drug Investig 44(10):789\u2013798","journal-title":"Clin Drug Investig"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05366-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:01:45Z","timestamp":1784775705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05366-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5366"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05366-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this study as it exclusively utilized de-identified, publicly available data from the FAERS, GWAS, and GEO databases. In accordance with the institutional requirements and the principles of the Declaration of Helsinki, neither formal ethical approval nor informed consent was required for this retrospective analysis of aggregate data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"While preparing this work, the authors used ChatGPT to polish the language. After using this tool, the authors reviewed and edited the content as needed and took full responsibility for the publication\u2019s content.","order":5,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}]}}